Search

Displaying results 5821 - 5830 of 7017 in total
  1. Drug

    PF-08046040

    go.drugbank.com/drugs/DB17555
    Investigational

    SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).

  2. Drug

    cAd3-Marburg vaccine

    go.drugbank.com/drugs/DB22520
    Investigational

    cAd3-Marburg vaccine is under investigation in clinical trial NCT06620003 (A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored

  3. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

    Categories: Adenosine A2 Receptor Antagonists
  4. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.

  5. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].

  6. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine. … A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged

  7. Drug

    Plozalizumab

    go.drugbank.com/drugs/DB12520
    Investigational

    The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. … Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation.

  8. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

  9. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    It is a member of a new family of pharmaceutical compounds called vomeropherins.

  10. Drug

    BZL101

    go.drugbank.com/drugs/DB05051
    Investigational

    BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.